Corrigendum | Published:

Knocking down barriers: advances in siRNA delivery

Nature Reviews Drug Discovery volume 8, page 516 (2009) | Download Citation

On page 136 in Table 3, the clinical trial for acute renal failure has been attributed to Quark/Pfizer when it should be attributed to Quark alone. In addition, the authors would like to clarify that, following a Phase I/II trial in patients with wet age-related macular degeneration, the siRNA drug candidate PF-4523655 (RTP801i-14) is now being studied in a Phase II trial for diabetic macular oedema conducted by Pfizer in collaboration with Quark.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd2919-c1

Authors

  1. Search for Kathryn A. Whitehead in:

  2. Search for Robert Langer in:

  3. Search for Daniel G. Anderson in:

Further reading